Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Neuroprotective pentapeptide CN-105 is associated with reduced sterile inflammation and improved functional outcomes in a traumatic brain injury murine model.

Laskowitz DT, Wang H, Chen T, Lubkin DT, Cantillana V, Tu TM, Kernagis D, Zhou G, Macy G, Kolls BJ, Dawson HN.

Sci Rep. 2017 Apr 21;7:46461. doi: 10.1038/srep46461.

2.

Apolipoprotein E mimetic peptide, CN-105, improves outcomes in ischemic stroke.

Tu TM, Kolls BJ, Soderblom EJ, Cantillana V, Ferrell PD, Moseley MA, Wang H, Dawson HN, Laskowitz DT.

Ann Clin Transl Neurol. 2017 Mar 9;4(4):246-265. doi: 10.1002/acn3.399. eCollection 2017 Apr.

3.

Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects.

Guptill JT, Raja SM, Boakye-Agyeman F, Noveck R, Ramey S, Tu TM, Laskowitz DT.

J Clin Pharmacol. 2017 Jun;57(6):770-776. doi: 10.1002/jcph.853. Epub 2016 Dec 19.

PMID:
27990643
4.

Delivery of a protein transduction domain-mediated Prdx6 protein ameliorates oxidative stress-induced injury in human and mouse neuronal cells.

Singh SP, Chhunchha B, Fatma N, Kubo E, Singh SP, Singh DP.

Am J Physiol Cell Physiol. 2016 Jan 1;310(1):C1-16. doi: 10.1152/ajpcell.00229.2015. Epub 2015 Oct 7.

5.

Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials.

Jia Q, Deng Y, Qing H.

Biomed Res Int. 2014;2014:837157. doi: 10.1155/2014/837157. Epub 2014 Jul 17. Review.

6.
7.

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.

Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G.

Nat Rev Neurol. 2013 Feb;9(2):106-18. doi: 10.1038/nrneurol.2012.263. Epub 2013 Jan 8. Review. Erratum in: Nat Rev Neurol. 2013. doi: 10.1038/nmeurol.2013.32. Liu, Chia-Chan [corrected to Liu, Chia-Chen].

8.
9.

Apolipoproteins in the brain: implications for neurological and psychiatric disorders.

Elliott DA, Weickert CS, Garner B.

Clin Lipidol. 2010 Aug 1;51(4):555-573.

10.

A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis.

Bhattacharjee PS, Huq TS, Mandal TK, Graves RA, Muniruzzaman S, Clement C, McFerrin HE, Hill JM.

PLoS One. 2011 Jan 6;6(1):e15905. doi: 10.1371/journal.pone.0015905.

11.

COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat.

Kaufman NA, Beare JE, Tan AA, Vitek MP, McKenna SE, Hoane MR.

Behav Brain Res. 2010 Dec 25;214(2):395-401. doi: 10.1016/j.bbr.2010.06.017. Epub 2010 Jun 19.

12.

An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury.

Li FQ, Fowler KA, Neil JE, Colton CA, Vitek MP.

J Pharmacol Exp Ther. 2010 Jul;334(1):106-15. doi: 10.1124/jpet.110.167882. Epub 2010 Apr 20.

13.

Full-length apolipoprotein E protects against the neurotoxicity of an apoE-related peptide.

Crutcher KA, Lilley HN, Anthony SR, Zhou W, Narayanaswami V.

Brain Res. 2010 Jan 8;1306:106-15. doi: 10.1016/j.brainres.2009.10.021. Epub 2009 Oct 21.

14.

Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy.

Bu G.

Nat Rev Neurosci. 2009 May;10(5):333-44. doi: 10.1038/nrn2620. Epub 2009 Apr 2. Review.

15.

COG1410 improves cognitive performance and reduces cortical neuronal loss in the traumatically injured brain.

Hoane MR, Kaufman N, Vitek MP, McKenna SE.

J Neurotrauma. 2009 Jan;26(1):121-9. doi: 10.1089/neu.2008.0565.

16.

Pharmacogenomic effects of apolipoprotein e on intracerebral hemorrhage.

James ML, Sullivan PM, Lascola CD, Vitek MP, Laskowitz DT.

Stroke. 2009 Feb;40(2):632-9. doi: 10.1161/STROKEAHA.108.530402. Epub 2008 Dec 24.

17.

COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia.

Tukhovskaya EA, Yukin AY, Khokhlova ON, Murashev AN, Vitek MP.

J Neurosci Res. 2009 Feb 15;87(3):677-82. doi: 10.1002/jnr.21874.

18.

N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein.

Sheng Z, Prorok M, Brown BE, Castellino FJ.

Neuropharmacology. 2008 Aug;55(2):204-14. doi: 10.1016/j.neuropharm.2008.05.016. Epub 2008 May 24.

19.

Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities.

Cedazo-Mínguez A.

J Cell Mol Med. 2007 Nov-Dec;11(6):1227-38. doi: 10.1111/j.1582-4934.2007.00130.x. Review.

20.

Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord.

Liu T, Donahue KC, Hu J, Kurnellas MP, Grant JE, Li H, Elkabes S.

J Proteome Res. 2007 Jul;6(7):2565-75. Epub 2007 Jun 16.

Supplemental Content

Support Center